Lack of a pharmacokinetic interaction between escitalopram and the CYP3A4 inhibitor ritonavir

被引：0
|
作者：
Gutierrez, M [1 ]
Abramowitz, W [1 ]
机构：
[1] Forest Labs, New York, NY USA
来源：
BIOLOGICAL PSYCHIATRY | 2001年 / 49卷 / 08期
关键词：
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
181
引用
收藏
页码：51S / 51S
页数：1
相关论文
共 50 条
  • [1] Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir
    Sevrioukova, Irina F.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2024, 758
  • [2] An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome p450 3A4 inhibitor ritonavir
    Gutierrez, MM
    Rosenberg, J
    Abramowitz, W
    CLINICAL THERAPEUTICS, 2003, 25 (04) : 1200 - 1210
  • [3] Lack of interaction between citalopram and the CYP3A4 substrate triazolam
    Nolting, A
    Abramowitz, W
    PHARMACOTHERAPY, 2000, 20 (07): : 750 - 755
  • [4] Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol
    Wiesinger, Herbert
    Berse, Matthias
    Klein, Stefan
    Gschwend, Simone
    Hchel, Joachim
    Zollmann, Frank S.
    Schuett, Barbara
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (06) : 1399 - 1410
  • [5] Interaction involving tadalafil and CYP3A4 inhibition by ritonavir
    Loulergue, Pierre
    Gaillard, Raphael
    Mir, Olivier
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (03) : 239 - U1
  • [6] A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
    Zdravkovic, M
    Olsen, AK
    Christiansen, T
    Schulz, R
    Taub, ME
    Thomsen, MS
    Rasmussen, MH
    Ilondo, MM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 58 (10) : 683 - 688
  • [7] A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate
    Milan Zdravkovic
    Anette K. Olsen
    Tina Christiansen
    Rainer Schulz
    Mitchell E. Taub
    Mikael S. Thomsen
    Michael H. Rasmussen
    Mapoko M. Ilondo
    European Journal of Clinical Pharmacology, 2003, 58 : 683 - 688
  • [8] Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates
    Umehara, Ken-ichi
    Huth, Felix
    Won, Christina S.
    Heimbach, Tycho
    He, Handan
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2018, 39 (03) : 152 - 163
  • [9] EFFECT OF DILTIAZEM, A MODERATE CYP3A4 INHIBITOR, ON THE PHARMACOKINETIC PARAMETERS OF TAMSULOSIN
    Lee, Y.
    Byeon, J. Y.
    Kim, Y. H.
    Kim, S. H.
    Lee, H. J.
    Lee, Y. J.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E61 - E62
  • [10] ASSESSMENT OF PHARMACOKINETIC INTERACTION BETWEEN THE PI3K INHIBITOR TASELISIB (GDC-0032) AND A STRONG CYP3A4 INDUCER OR INHIBITOR.
    Sahasranaman, S.
    Graham, R. A.
    Salphati, L.
    Hsu, J.
    Lu, X.
    Gates, M.
    Amin, D.
    Bradford, D.
    Dresser, M.
    Ware, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S80 - S81
12345